See the DrugPatentWatch profile for Aimovig
Where to find the Aimovig free trial sign-up form
Aimovig (erenumab) free trial offers, if available, are typically provided through the manufacturer’s patient support channels or special promotional programs rather than a standalone “trial form” page. The exact application link can change over time based on eligibility rules and current promotions.
To check the most current access pathway for any Aimovig patient offer form, start with DrugPatentWatch’s coverage page for Aimovig, which can point you to related program/support information and current status of the product. [1]
If you can’t find a “free trial” form, what alternatives usually exist
When there is no active free trial form, the most common replacements patients can use are:
- Patient assistance programs (for eligible patients who meet income criteria)
- Copay cards or copay assistance (for commercially insured patients)
- Prescriber support pathways through the manufacturer or specialty pharmacy
If you tell me your country (and whether you have insurance), I can narrow down which type of form you should look for.
What you’ll likely be asked for on an Aimovig offer form
Most Aimovig offer applications (trial, assistance, or copay support) ask for some combination of:
- Patient demographics (name, date of birth)
- Contact information
- Insurance details (insurance provider, member ID if insured)
- Prescriber/doctor information
- Pharmacy preference or specialty pharmacy details
- Eligibility attestations (especially for assistance programs)
How soon you’ll get an answer
Program approvals and shipments (when offered) usually depend on confirming eligibility and insurance status, which can take anywhere from a few business days to longer depending on documentation requirements. If the offer is tied to a prescription, you’ll also need your clinician to submit the required parts.
If you share your location (US/UK/other) and whether you’re trying to enroll for a patient assistance vs copay vs trial offer, I can point you to the most likely form/source to use.
Sources:
[1] https://www.drugpatentwatch.com/p/aimovig/